One Patient One Cure: Comprehensive Company Profile

Background

Overview

One Patient One Cure is a U.S.-based 501(c)(3) nonprofit organization dedicated to revolutionizing healthcare through cutting-edge science and technology. The organization focuses on advancing research, accelerating drug discovery, and pioneering personalized medicine by integrating artificial intelligence (AI) with deep biological insights.

Mission and Vision

The mission of One Patient One Cure is to make precision medicine accessible to every patient, regardless of their condition or location. By harnessing AI and multi-omics data, the organization aims to provide tailored treatments that reflect the full complexity of each patient, moving beyond traditional "one-size-fits-all" approaches.

Primary Area of Focus

The organization specializes in precision oncology, particularly targeting rare cancers and complex tumor profiles that often fall outside standard clinical trial populations. By integrating multi-omics data—such as genomics, transcriptomics, and proteomics—with intelligent machine learning, One Patient One Cure seeks to predict the most effective treatments for individual cancer patients based on their unique biological features.

Industry Significance

In the rapidly evolving field of precision medicine, One Patient One Cure stands out by focusing on underserved patient populations, including those with rare cancers and complex tumor profiles. Its innovative approach to integrating AI with multi-omics data positions the organization as a leader in making personalized healthcare both affordable and globally accessible.

Key Strategic Focus

Core Objectives

• Advancing Research: Conducting cutting-edge research to uncover new insights into cancer biology and treatment.

• Accelerating Drug Discovery: Utilizing AI and multi-omics data to expedite the identification of effective cancer therapies.

• Pioneering Personalized Medicine: Developing AI-driven models that provide tailored treatment recommendations for individual patients.

Specific Areas of Specialization

The organization specializes in precision oncology, focusing on rare cancers and complex tumor profiles that are often excluded from traditional clinical trials. By integrating multi-omics data with machine learning, One Patient One Cure aims to predict the most effective treatments for each patient based on their unique biological features.

Key Technologies Utilized

• Artificial Intelligence (AI): Employing machine learning algorithms to analyze complex biological data and predict treatment outcomes.

• Multi-Omics Data Integration: Combining genomics, transcriptomics, and proteomics data to gain a comprehensive understanding of cancer biology.

• Ex Vivo Drug Testing: Developing methods to test drug efficacy using a patient's own cells, ensuring personalized treatment effectiveness.

Primary Markets or Conditions Targeted

One Patient One Cure primarily targets patients with rare cancers and complex tumor profiles, aiming to provide personalized treatment options that are often unavailable through traditional clinical trials. The organization also collaborates with researchers and pharmaceutical companies to accelerate target identification and drug discovery.

Financials and Funding

Funding History

As a nonprofit organization, One Patient One Cure relies on philanthropic support, grants, and donations to fund its operations and research initiatives. Specific details regarding total funds raised and recent funding rounds are not publicly disclosed.

Notable Investors

While specific investors are not publicly listed, the organization has established partnerships with various stakeholders, including research institutions and healthcare organizations, to advance its mission.

Intended Utilization of Capital

The funds are primarily utilized for:

• Research and Development: Advancing AI-driven models and conducting multi-omics research.

• Clinical Trials: Implementing validation studies in collaboration with institutions like the Dana-Farber Cancer Institute.

• Operational Expenses: Supporting the organization's day-to-day operations and strategic initiatives.

Pipeline Development

Key Pipeline Candidates

• CureCancer Model: An AI-powered drug response prediction model set to launch in 2026. Trained on matched multi-omics and drug sensitivity datasets from approximately 1,000 cancer models, CureCancer is designed to predict the most effective treatment for each patient based on their unique biological features.

Stages of Clinical Trials or Product Development

The CureCancer model is currently in the development phase, with plans for validation studies underway. A validation study in acute myeloid leukemia is currently underway in active collaboration with Dana-Farber Cancer Institute.

Target Conditions

The primary focus is on various cancer types, particularly rare cancers and complex tumor profiles that are often excluded from standard clinical trials.

Relevant Timelines for Anticipated Milestones

• 2026: Launch of the CureCancer model.

• 2030: Goal to make CureCancer accessible worldwide at an average cost of no more than $1,000 per patient, from biopsy to drug prediction.

Technological Platform and Innovation

Proprietary Technologies

• CureCancer Model: An AI-driven model that integrates multi-omics data to predict the most effective cancer treatments for individual patients.

Significant Scientific Methods

• Multi-Omics Data Integration: Combining genomics, transcriptomics, and proteomics data to gain a comprehensive understanding of cancer biology.

• Ex Vivo Drug Testing: Developing methods to test drug efficacy using a patient's own cells, ensuring personalized treatment effectiveness.

Leadership Team

Qingyu Luo, MD, PhD – Co-founder and President

Qingyu earned his medical degree in clinical medicine from Dalian Medical University and completed his PhD at Peking Union Medical College. He has led over 10 collaborative translational research projects and was awarded the Dean’s Award. At Dana-Farber Cancer Institute, he pioneered methods to convert complex biological features into predictive biomarkers for leukemia treatment response. He serves as the co-founder and president of One Patient One Cure, merging his expertise in medicine and biology with artificial intelligence to realize a new era of personalized, accessible, and cost-effective healthcare.

Humam Zaman – Co-founder and Vice President of Global Outreach

Humam is a pioneering AI entrepreneur and CEO of The Tech Valley, leading a multidisciplinary team of over 20 professionals. He has successfully delivered more than 140 AI-powered projects across various sectors, including healthcare, and has collaborated with major organizations such as Google, Hugging Face, OpenAI, and Mayo Clinic. As co-founder and interim technical officer of One Patient One Cure, he leads the development of the organization’s AI predictor models and serves as Vice President of Global Outreach to advance the mission internationally.

Anthony R. Franco, JD – Board Member

Anthony brings over 20 years of experience bridging legal, operational, and biotech domains. As Chief Operating Officer and Co-Founder of ReST Therapeutics US, he leads fundraising, product development, and regulatory strategy. His prior executive roles at Infinant Health and Alexion Pharmaceuticals included managing global operations, capital planning, and digital transformation initiatives. His expertise in commercialization, long-term planning, and systems implementation supports One Patient One Cure in growing sustainably while staying true to its mission.

Barbara Hales, MD – Board Member

Barbara contributes a rare dual perspective as both a seasoned physician and a skilled communicator. With over 30 years of clinical experience in Obstetrics and Gynecology and a thriving career as a medical writer and content strategist, she bridges the gap between science and storytelling. She is the author of "Power to the Patient: The Medical Strategist" and "EMR Guide—Choosing Without Losing," and served as editor of The Medical Strategist newsletter. Her ability to make complex medical topics accessible ensures that One Patient One Cure maintains clear, compassionate communication while advancing AI-driven precision medicine.

Henry Hagopian – Board Member

Henry brings a wealth of financial expertise shaped by more than 30 years in biotech, healthcare, and technology. He has held senior leadership roles including CFO of Annovis Bio and SVP at Organogenesis, where he navigated IPOs, SEC reporting, major fundraising rounds, and M&A activity. His experience includes negotiating high-value credit facilities, enhancing investor relations, and leading enterprise-wide financial systems upgrades. With both Wall Street acumen and operational execution skills, Henry ensures that One Patient One Cure has the financial discipline and resilience to support its ambitious vision.